Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
23.48
+0.09 (0.38%)
May 28, 2026, 1:42 PM EDT - Market open
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,371 employees as of December 31, 2025. The number of employees increased by 77 or 5.95% compared to the previous year.
Employees
1,371
Change (1Y)
77
Growth (1Y)
5.95%
Revenue / Employee
$488,694
Profits / Employee
-$444,201
Market Cap
2.31B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,371 | 77 | 5.95% |
| Dec 31, 2024 | 1,294 | 18 | 1.41% |
| Dec 31, 2023 | 1,276 | -35 | -2.67% |
| Dec 31, 2022 | 1,311 | 192 | 17.16% |
| Dec 31, 2021 | 1,119 | 226 | 25.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Vera Therapeutics | 339 |
| Immunome | 206 |
| Celldex Therapeutics | 198 |
| Kodiak Sciences | 130 |
| Pharvaris | 129 |
| Definium Therapeutics | 106 |
| Mineralys Therapeutics | 76 |
RARE News
- 5 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Ultragenyx price target raised to $96 from $84 at Cantor Fitzgerald - TheFly
- 14 days ago - Ultragenyx Pharmaceutical Transcript: AGM 2026 - Transcripts
- 15 days ago - Ultragenyx Pharmaceutical Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Ultragenyx price target lowered to $33 from $34 at Evercore ISI - TheFly
- 20 days ago - Ultragenyx price target lowered to $26 from $27 at Wedbush - TheFly
- 20 days ago - Ultragenyx price target lowered to $43 from $52 at Guggenheim - TheFly
- 21 days ago - Rare disease families find roadmap to drug development at bootcamps - CNBC